Previous Close | 325.92 |
Open | 327.00 |
Bid | 327.50 x 100 |
Ask | 327.75 x 100 |
Day's Range | 322.39 - 327.94 |
52 Week Range | 249.70 - 346.85 |
Volume | |
Avg. Volume | 2,074,153 |
Market Cap | 176.042B |
Beta (5Y Monthly) | 0.61 |
PE Ratio (TTM) | 56.49 |
EPS (TTM) | 5.80 |
Earnings Date | Oct 29, 2024 - Nov 04, 2024 |
Forward Dividend & Yield | 9.00 (2.76%) |
Ex-Dividend Date | Aug 16, 2024 |
1y Target Est | 328.27 |
Viridian Therapeutics stock jumped Tuesday after unveiling promising results for its Amgen-rivaling eye disease treatment.
Amgen (NASDAQ:AMGN) today announced the presentation of new data showcasing IMDELLTRATM (tarlatamab-dlle), a first-in-class delta-like ligand 3 (DLL3)-targeting Bispecific T-cell Engager (BiTE®) molecule, at the 2024 World Conference on Lung Cancer (WCLC) in San Diego.
We recently compiled a list of the 12 Best Biotech Stocks To Invest In According To Hedge Funds. In this article, we are going to take a look at where Amgen Inc. (NASDAQ:AMGN) stands against the other biotech stocks. As we have mentioned in our article, “10 Best Penny Stocks to Buy Under $1,” the size […]